
Capital investments in production plants represent a significant portion of the cost of new recombinant drugs
Yann Echelard, PhD is vice president of research and development at GTC Biotherapeutics, Inc.

Capital investments in production plants represent a significant portion of the cost of new recombinant drugs

Published: August 1st 2006 | Updated: